EP4021912A4 - Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer - Google Patents

Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer Download PDF

Info

Publication number
EP4021912A4
EP4021912A4 EP20857153.9A EP20857153A EP4021912A4 EP 4021912 A4 EP4021912 A4 EP 4021912A4 EP 20857153 A EP20857153 A EP 20857153A EP 4021912 A4 EP4021912 A4 EP 4021912A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
inhibitor prodrugs
tyrosine kinas
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20857153.9A
Other languages
German (de)
English (en)
Other versions
EP4021912A1 (fr
Inventor
Jiasheng LU
Jiamin GU
Gang Chen
Qiguo Zhang
Chengyong SUN
Xianqi Kong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Risen Suzhou Pharma Tech Co Ltd
Original Assignee
Risen Suzhou Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910818779.0A external-priority patent/CN112442011B/zh
Priority claimed from CN201910817505.XA external-priority patent/CN112442009B/zh
Priority claimed from CN201910818675.XA external-priority patent/CN112442010B/zh
Application filed by Risen Suzhou Pharma Tech Co Ltd filed Critical Risen Suzhou Pharma Tech Co Ltd
Publication of EP4021912A1 publication Critical patent/EP4021912A1/fr
Publication of EP4021912A4 publication Critical patent/EP4021912A4/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20857153.9A 2019-08-30 2020-08-28 Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer Pending EP4021912A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910818779.0A CN112442011B (zh) 2019-08-30 2019-08-30 一种前药化合物及其在治疗癌症方面的应用
CN201910817505.XA CN112442009B (zh) 2019-08-30 2019-08-30 氘代化合物及其在治疗癌症方面的应用
CN201910818675.XA CN112442010B (zh) 2019-08-30 2019-08-30 一类前药化合物及其在治疗癌症方面的应用
US202062994364P 2020-03-25 2020-03-25
PCT/CA2020/051177 WO2021035360A1 (fr) 2019-08-30 2020-08-28 Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer

Publications (2)

Publication Number Publication Date
EP4021912A1 EP4021912A1 (fr) 2022-07-06
EP4021912A4 true EP4021912A4 (fr) 2023-08-23

Family

ID=74684795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20857153.9A Pending EP4021912A4 (fr) 2019-08-30 2020-08-28 Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer

Country Status (5)

Country Link
EP (1) EP4021912A4 (fr)
AU (1) AU2020338490B2 (fr)
CA (1) CA3147801A1 (fr)
IL (1) IL290798B1 (fr)
WO (1) WO2021035360A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250092013A1 (en) * 2021-10-15 2025-03-20 Ocular Therapeutix, Inc. Prodrugs of axitinib
WO2024032584A1 (fr) * 2022-08-08 2024-02-15 苏州必扬医药科技有限公司 Inhibiteur de protéine tyrosine kinase et son utilisation médicale
CN120329323B (zh) * 2025-04-16 2026-01-13 黄冈鲁班药业股份有限公司 一种头孢吡普酯侧链的制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106317017A (zh) * 2015-07-10 2017-01-11 李建成 一种作为治疗眼科疾病的新化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CN106336397A (zh) * 2015-07-07 2017-01-18 郭明山 一种作为治疗眼科疾病的新化合物
CN106478596A (zh) * 2015-08-25 2017-03-08 李建成 一种作为治疗眼科疾病的新化合物
CN110372598A (zh) 2018-04-13 2019-10-25 成都海创药业有限公司 一种合成氘代酰胺及氘代磺酰胺的新方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106317017A (zh) * 2015-07-10 2017-01-11 李建成 一种作为治疗眼科疾病的新化合物

Also Published As

Publication number Publication date
AU2020338490B2 (en) 2025-09-18
WO2021035360A1 (fr) 2021-03-04
EP4021912A1 (fr) 2022-07-06
IL290798B1 (en) 2026-02-01
AU2020338490A1 (en) 2022-03-17
CA3147801A1 (fr) 2021-03-04
IL290798A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
EP3589289A4 (fr) Inhibition de smarca2 pour le traitement du cancer
EP4126843C0 (fr) Composés d'oxoisoindoline substitués pour le traitement du cancer
EP4017489C0 (fr) Dgd1202 pour le traitement des cancers à mutation kras
EP4171548A4 (fr) Polythérapie pour le traitement du cancer
EP3883580A4 (fr) Méthodes de traitement de cancers
EP4337329A4 (fr) Combinaisons pour le traitement du cancer
EP3464643A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP4067347C0 (fr) Inhibiteurs hétérocycliques de cbp/ep300 pour le traitement du cancer
EP3678663A4 (fr) Polythérapie pour le traitement du cancer
EP3565558A4 (fr) Polythérapie pour le traitement du cancer
EP3943093C0 (fr) Utilisation d'akkermansia pasteurisé pour traiter du cancer
EP3823653A4 (fr) Bactérie programmable destinée au traitement du cancer
EP3995139C0 (fr) Composition pour utilisation dans le traitement du cancer
EP3566055C0 (fr) Inhibiteurs de la scd pour le traitement de troubles neurologiques
EP4031543A4 (fr) Biaminoquinolines et nanoformulations pour le traitement du cancer
EP3897626C0 (fr) Tinostamustine pour le traitement du myélome multiple
EP4259639A4 (fr) Polythérapies pour le traitement du cancer
EP3573620A4 (fr) Compositions pour le traitement de l'hypertension
EP4259638A4 (fr) Polythérapies pour le traitement du cancer
EP4021912A4 (fr) Promédicaments de l'inhibiteur de tyrosine kinase pour le traitement du cancer
EP3843773A4 (fr) Inhibition de kinases ripk pour traiter des maladies neurodégénératives
EP4149943A4 (fr) INHIBITEUR DE VCP/p97 POUR LE TRAITEMENT DU CANCER
EP4423251A4 (fr) Macrophages déficients en sirp alpha pour traiter un cancer
EP4058041C0 (fr) Compositions pour le traitement de lésions épithéliales
EP4419504A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220322

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230725

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/12 20060101ALI20230719BHEP

Ipc: C07D 401/14 20060101ALI20230719BHEP

Ipc: C07D 401/06 20060101ALI20230719BHEP

Ipc: A61P 35/00 20060101ALI20230719BHEP

Ipc: A61K 31/675 20060101ALI20230719BHEP

Ipc: A61K 31/4439 20060101ALI20230719BHEP

Ipc: C07F 9/6558 20060101AFI20230719BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RISEN (SUZHOU) PHARMA TECH CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250522